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Original research
Community acquired pneumonia (CAP) is a common and 
serious illness. Most CAP patients are treated in outpatient 
facilities and only 20% of CAP patients require hospitalization 
[1]. Among hospitalized CAP patients, the majority of deaths 
occur during the early days of hospitalization [2]. Early 
recognition of severity of CAP is essential for initiation of 
appropriate empiric antibiotic treatment, aggressive diagnostic 
work-up, and adequate supportive care. Management strategies 
for CAP patients depend on the severity of CAP and risk of 
mortality. In patients with severe CAP, a respiratory specimen 
does not always yield a positive microbiological culture or 
definitive pathogen.  Furthermore, there is no single factor 
which can predict the severity of CAP [3].
Physicians frequently use scoring systems to assess the severity 
of disease and to predict likely clinical outcomes [4]. However, 
these scores have limitations, including age of the patient, 
failure to account for certain comorbidities, and other social 
factors [5]. These limitations have led to exploring the use of 
biomarkers to improve clinical management of patients with 
CAP. To aid clinicians in predicting risk and to treat patients 
with CAP, biomarkers can provide rapid information [3] and 
supplement accepted clinical scoring systems. Biomarkers 
provide quantitative information which is easy to interpret, 
reliable and reproducible. One of the biomarkers used to predict 
clinical outcomes is C-reactive protein (CRP).
 
CRP is named for its ability to interact with C-polysaccharide 
within the cellular wall of Streptococcus pneumoniae [6], and 
this interaction labels them for opsonization. CRP is an acute 
phase protein which is predominantly synthesized by the liver 
[7] in response to inflammatory cytokines IL-6, IL-1β or TNF-
alpha [8], particularly in response to infection and tissue injury. 
These inflammatory cytokines are produced by macrophages 
and monocytes to destroy the pathogens at the site of infection 
or injury. CRP has a half-life of 19 hours in plasma [9]. Once 
the inflammatory stimulus is removed, the CRP level decreases 
rapidly.  Several studies have documented that the serum CRP 
level serves as a good marker for diagnosis of CAP and predicts 
clinical severity of disease [10, 11], although the absolute 
CRP levels used for clinical decisions vary considerably. For 
conventional serum CRP assays approved by FDA [12], however, 
the typical cutoffs are broken out in in the following manner: 
healthy individuals:  less than or equal to 5 mg/L, Acute range: 
20-500 mg/L.
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Abstract
Finding relevant biomarkers as a potential predictor of severity for patients hospitalized with 
community acquired pneumonia (CAP), in addition to the clinical scoring system, could advance 
progress towards more effective patient management. The inflammatory marker, C-reactive protein 
(CRP), which is elevated in the pathogenesis of many infectious diseases, may be a key biomarker 
target for CAP. Previous studies have shown that serum CRP may be a useful diagnostic marker for 
pneumonia in hospitalized patients with acute respiratory symptoms. The main aims of this study were 
to determine the correlation between serum and urine CRP levels in hospitalized patients with CAP, 
and any correlation with patient outcomes. Our laboratory employed a commercially available human 
high sensitive CRP ELISA kit to check the level of CRP in the corresponding patient urine sample. 
The results showed that there was a positive correlation between patient serum and urine CRP levels. 
In addition, we showed the correlation of urine CRP levels with certain patient comorbidities, time to 
clinical stability, length of patient hospital stay, and mortality.
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Despite the evidence supporting use of CRP as a biomarker, 
there are no studies to our knowledge documenting a correlation 
between blood and urine CRP levels; thus, a highly sensitive 
CRP assay was chosen for urine sample testing since expected 
levels were completely unknown.  In addition, there was no 
established relationship between CRP levels and key outcomes 
for patients hospitalized with CAP. 
The primary objective of this initial laboratory study was to 
define the relationship between serum and urine CRP levels in 
patients hospitalized with CAP.  The secondary objectives were 
to 1) analyze the relationship between CRP levels and clinical 
data, and 2) define the relationship between CRP levels and 
clinical outcomes of patients hospitalized due to CAP.
Materials and Methods
Study design and study population 
This was a secondary data analysis of the University of 
Louisville’s two large pneumonia studies, prospective 
population-based cohort studies of all hospitalized adults with 
CAP who were residents in the city of Louisville, Kentucky, from 
June 1st 2014 to May 31st 2016 (University of Louisville IRB 
Numbers 11.0613 and 13.0408) [13]. Patients were enrolled if 
they meet inclusion criteria for diagnosis of CAP.
 
Inclusion criteria
A diagnosis of CAP required radiographic criteria, clinical 
criteria and initiation of antibiotics within 24 hours of 
admission. 
• Radiographic criteria: A new pulmonary infiltrate on 
imaging (computed tomography or chest x-ray) at the time 
of admission.
• Specific clinical signs: included new or increased cough, 
fever > 37.8°C (100.0°F) or hypothermia <35.6°C (96.0°F) 
or change in serum white blood cells (leukocytosis >11,000 
cells/mm3, left shift >10% band forms/microliter, or 
leukopenia < 4,000 cells/mm3).
Urine was collected from patients once they were enrolled in 
study in the University of Louisville Pneumonia study [13]. 
Among these enrolled patients, patients with documented 
serum CRP in first 24 hours of hospital admission in medical 
record were included in  this study.
Study Outcomes
Study outcomes analyzed in this study included length of stay 
(LOS), time to clinical stability (TCS) and mortality. Time to 
clinical stability was defined as the day patient met the following 
four criteria: (1) improvement in cough and shortness of breath, 
(2) lack of fever for at least 8 hours, (3) improved leukocytosis 
and (4) tolerance to oral intake.  Patients were evaluated daily 
for first seven days of hospitalization to determine the day 
when clinical stability was reached; however, patients still 
unstable at day seven were censored at eight days. Length of stay 
was defined as number of days from admission to discharge. 
Patients hospitalized for more than 14 days were censored at 14 
days. Mortality (any cause) was evaluated from admission to up 
to one year after admission.
Patient Groupings
The samples used in this preliminary study were selected based 
on patient serum CRP levels obtained from hospital records. 
The serum CRP level was collected within the first 24 hours of 
hospitalization.  The urine samples from patients were collected 
after enrollment within the first 48 hours of hospitalization. The 
urine samples were divided into three groups: low, intermediate 
and high according to serum CRP levels (1-10 mg/L, 11-50 
mg/L, 51-270 mg/L, respectively) (Figure 1A). Processing 
and storing of the urine samples can be found in the “Sample 
Selection” section. There were ten consented patient urine 
samples included in each CAP group, plus consented healthy 
volunteers provided urine samples that were used as controls 
(no CAP).  Supplemental information for all pneumonia patients 
is included in Table 1. 
Sample processing and selection 
Archived urine samples from University of Louisville 
Respiratory Specimen Biorepository in the Division of 
Infectious Diseases were used. Urine specimens selected for 
this study were collected from July 2014 to January 2016 [13] 
under IRB Numbers  11.0613 and 13.0408.  Briefly, the original 
urine samples from patients hospitalized with CAP were held 
at 4°C, then processed within 28 hours of collection by adding 
0.5 mL of 0.5 M PIPES buffer (VWR, Radnor, PA, part number 
BB-121-250 mL) to 9.5 mL of urine. After mixing well, aliquots 
were frozen at -80°C until thawed.  Next, 1 mL of thawed urine 
sample was centrifuged at 300xg for 5 minutes and 240 µL of 
supernatant was aliquoted into each of four tubes for this study. 
These aliquoted samples were frozen at -20°C until thawed for 
the enzyme-linked immunosorbent assay (ELISA) described 
below.  The same urine processing protocol was followed for 
urine samples from healthy volunteers. All samples were tested 
undiluted (raw) in duplicate and the ELISA was repeated three 
times independently. 
Human highly sensitive enzyme-linked immunosorbent assay 
for C reactive protein (CRP-ELISA)
The human high sensitive CRP-ELISA was obtained from 
MyBioSource, Inc. (Research Use Only, Cat. No: MBS2021863, 
San Diego, CA). Urine samples were thawed, and brought 
to room temperature prior to using 100 µL of raw urine. 
The sandwich ELISA assay was performed following the 
manufacturer’s instructions.  Briefly, blanks and standards 
were included in each run by adding 100 µL of each dilution 
of standards and blanks, as well as samples (in duplicate) into 
the appropriate wells. After covering the plate and incubating 
for one hour at 37°C, the samples were removed manually and 
100 µL of Detection Reagent A were added (biotin-conjugated 
antibody specific to human CRP). After re-covering the plate, 
incubation proceeded for one hour at 37°C. Detection Reagent 
A was removed and wells were washed three times manually 
with wash buffer.  Next, 100 µL of Detection Reagent B (avidin-
conjugated horseradish peroxidase) was added to each well.  The 
plate was again covered and incubated for 30 minutes at 37°C. 
Detection Reagent B was manually removed and all wells were 
washed five times manually with wash buffer. Finally, 90 µL of 
TMB substrate solution (3,3’,5,5’-Tetramethylbenzidine) was 
added to each well, and the plate was covered and incubated 10-
20 minutes at 37°C, protected from light. The stop solution was 
added, changing the color from blue to yellow, and the plate was 
read at 450 nM using a spectrophotometer. The unknown urine 
sample concentrations were determined by extrapolating from 
standards run on the same plate on the same day. The minimum 
detectable amount of CRP is typically less than 23.3 pg/mL. This 
assay has high sensitivity and excellent specificity for detection 
of human CRP, noting that a CRP concentration above 4000 pg/
mL was outside the linear range of the ELISA.
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Table 1.  Supplemental Information for Pneumonia Patients:  Clinical Features
Variable High Intermediate Low p
n 10 10 10
Demographics
Age (median [IQR]) 70 [64-78] 59 [50-78] 66 [52-76] 0.577
Male Sex (%) 3 (30) 7 (70) 7 (70) 0.114
Black Race (%) 2 (20) 1 (10) 0 (0) 0.329
Social/Medical History (n (%))
Obese 1 (10) 6 (60) 4 (40) 0.065
Hx HIV 0 (0) 1 (10) 0 (0) 0.355
Hx Neoplastic Disease 1 (10) 3 (30) 1 (10) 0.383
Hx Renal Disease 2 (20) 3 (30) 2 (20) 0.830
Hx CHF 3 (30) 0 (0) 3 (30) 0.153
Hx COPD 3 (30) 4 (40) 3 (30) 0.861
Hx Stroke 0 (0) 1 (10) 2 (20) 0.329
Hx Liver Disease 2 (20) 0 (0) 2 (20) 0.315
Hx Diabetes 5 (50) 4 (40) 4 (40) 0.873
Smoking History 0.482
Current 2 (20) 2 (20) 5 (50)
Former 5 (50) 4 (40) 2 (20)
Never 3 (30) 4 (40) 3 (30)
Cardiovascular Risk Factors and Medications (n (%))
Family Hx CAD 5 (50) 0 (0) 3 (30) 0.039
Active CAD 4 (40) 2 (20) 5 (50) 0.366
Arterial Hypertension 7 (70) 7 (70) 8 (80) 0.843
Hyperlipidimia 6 (60) 3 (30) 8 (80) 0.076
Hx Prior MI 2 (20) 2 (20) 3 (30) 0.830
Hx Prior PCTA 3 (30) 1 (10) 4 (40) 0.303
Atrial Fibrillation 1 (10) 1 (10) 2 (20) 0.749
Asprin Use 5 (50) 4 (40) 3 (30) 0.659
Beta Blocker Use 4 (40) 3 (30) 6 (60) 0.387
Ace Inhibitor Use 2 (20) 3 (30) 2 (20) 0.830
Warfarin Use 1 (10) 0 (0) 2 (20) 0.329
Heparin Use 1 (10) 0 (0) 0 (0) 0.355
Antiplatelet Use 1 (10) 0 (0) 1 (10) 0.585
Statin Use 5 (50) 4 (40) 3 (30) 0.659
Physical Exam and Laboratory Findings (median [IQR])
Temperature (degrees Celsius) 38 [37-38] 37 [37-38] 37 [37-37] 0.150
Respiratory Rate (breaths/min) 22 [20-24] 22 [18-24] 19 [16-24] 0.535
Heart Rate (beats/min) 106 [97-124] 116 [106-123] 81 [72-102] 0.024
Systolic Blood Pressure (mmHg) 108 [98-116] 118 [109-141] 134 [122-158] 0.020
Diastolic Blood Pressure (mmHg) 54 [46-66] 59 [52-68] 74 [63-92] 0.109
Bicarbonate (mEq/L) 28 [25-29] 24 [22-25] 26 [25-26] 0.067
Blood urea nitrogen (mg/dL) 14 [12-27] 24 [18-29] 16 [11-20] 0.159
Glucose (mg/dL) 143 [123-176] 197 [130-271] 104 [102-130] 0.057
Hematocrit (Percent) 30 [28-34] 38 [30-42] 35 [33-44] 0.136
Sodium (mEq/L) 136 [136-139] 136 [130-140] 138 [134-139] 0.775
Severity of Disease (n (%))
Direct admission to ICU 1 (10) 1 (10) 1 (10) >0.999
Altered mental status 3 (30) 1 (10) 4 (40) 0.303
Need for vasopressors 0 (0) 0 (0) 0 (0) >0.999
Need for ventilatory support 0 (0) 1 (10) 1 (10) 0.585
PSI* Risk Class IV-V 8 (80) 4 (40) 5 (50) 0.171
*Pneumonia Severity Index
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Statistical Analysis 
Simple linear regression was performed to define the 
relationships between serum CRP and urine CRP. Laboratory 
values that had a p-value of less than 0.2 were identified for 
further investigation; Pearson and Spearman correlation was 
performed to analyze associations between CRP levels and 
laboratory values.  Patient characteristics were summarized 
by group with descriptive statistics. Continuous data was 
reported as mean and interquartile range; categorical data was 
represented as frequency and percentage. Differences in patient 
characteristics were tested by Fisher’s Exact test for categorical 
data and the Kruskal-Wallis Rank Sum Test for continuous data. 
Kaplan-Meier curves were created to visualize outcomes, and 
log-rank tests were used to compare outcomes among groups. 
Microsoft Excel and R version 3.5.1 were used for analysis.
Results
Clinical characteristics of the three CRP groups
The serum CRP level as collected from patient’s medical record 
have been arranged by low, intermediate and high serum CRP 
level groups (Figure 1A). We were able to detect CRP in urine 
with the  human CRP-ELISA in the picogram range from urine 
samples collected from 30 patients with CAP; note that these 
data were arranged by serum CRP groups (Figure 1B). Also, 
CRP levels detected in urine samples were collected from 10 
healthy volunteers as controls (Figure 1B). All three groups 
of pneumonia patients show increased levels of urine CRP level 
when compared to healthy volunteers.  Intermediate Serum CRP 
group showed higher level of urine CRP as compared to high 
serum CRP level group.  Patient characteristics were collected 
from medical records (Table 1). Systolic blood pressure, heart 
rate, and family history of coronary artery disease were found 
to be significantly statistically different between CRP groups. 
The intermediate group had higher numbers of patients who 
were obese, HIV-infected, with a history of neoplastic disease 
or elevated blood glucose levels, but these were statistically not 
significant.
Relationship between serum and urine CRP
The relationship between log serum and log urine CRP was 
positive and linear (Figure 2). An increase of 1 log mg/L of 
serum CRP was indicative of an increase of 0.4 log pg/mL of 
urine CRP (β=0.4, p=0.002, R2 = 0.29).  
Correlation between CRP and other laboratory values
Laboratory values identified for follow-up analysis were 
temperature, heart rate, systolic blood pressure, diastolic 
blood pressure, serum bicarbonate, blood urea nitrogen, 
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Figure 1. CRP level of pneumonia patients. A) Level of serum CRP on pneumonia patients. Using data obtained from hospital records, these 
pneumonia patients’ urine samples were divided into three groups according to serum CRP levels, each group having 10 patients assigned a unique 
subject identification number (Serum CRP 1-10 mg/L, 11-50 mg/L, 51-270 mg/L). B) Level of urine CRP on healthy volunteers and pneumonia 
patients. Urine samples from 10 healthy volunteers and 30 pneumonia patients were tested using a human highly sensitive enzyme linked 
immunosorbent assay for C-reactive protein (CRP). All samples were run duplicate in each ELISA, and the values shown represent mean ± SD from 
three independent experiments.
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serum glucose, and hematocrit. Scatterplots were produced to 
illustrate log serum and log urine CRP levels compared to these 
laboratory values (Figures 3 and 4). Correlations ranged from 
-0.42 to 0.43.  After adjusting for multiple comparisons, no 
correlations were statistically significant.
CAP Patient Outcomes
We did not find statistically significant differences between 
groups for time to clinical stability and mortality at 1 year. Length 
of stay was found to be statistically significant between groups. 
Patient outcomes and statistical tests are shown in Table 2. 
Kaplan-Meier curves for time to clinical stability, length of 
stay, and mortality are shown in Figures 5-7, respectively, and 
summarized in Table 2.
Discussion
We observed increased urine CRP levels in pneumonia patients 
(Figure 1B) as compared to healthy volunteers, and there was a 
significant positive correlation of CRP levels between serum and 
urine samples (Figure 2). Studies have shown that markedly 
elevated serum CRP levels are strongly associated with bacterial 
infection [14]. CRP levels have been demonstrated to increase 
with pneumonia, confirming bacterial pneumonia in children 
[15, 16], as well as adult HIV-infected inpatients [17].  It has 
been recommended, however, to combine serum CRP values 
with other clinical prediction parameters to better identify 
patients with severe pneumonia and at risk of poor outcomes. 
Many common laboratory values (such as hematocrit, glucose 
and blood urea nitrogen levels) were not statistically significantly 
correlated with either serum or urine CRP levels (Figures 3 
and 4). TCS was not significantly correlated with CRP levels 
(Figure 5); however, the patient’s LOS at the hospital increased 
in direct proportion to increasing CRP levels (Figure 6).  Some 
possible explanations for this correlation may include the direct 
link between inflammation and fever due to release of pyrogens, 
increased circulating levels of IL-6 and IL-10 cytokines [18] or 
complications of inflammation that lead to longer hospital stays, 
such as myocardial infarctions [19, 20]. 
We found 50% mortality in the high CRP group, and 30% of 
mortality in both the intermediate and low CRP groups in the 
present study (Figure 7).  While the number of patients is low 
in this preliminary study, increasing the number of patients 
in future propspective studies may increase the statistical 
significance of these findings.  Ramirez et al [13] and other 
investigators  [21-23] stated that patients hospitalized with CAP 
showed a higher mortality rate compared to those without CAP. 
Another multi-center, one-year follow-up study with patients 
discharged after hospitalization for CAP found elevated pro-
inflammatory marker IL-6 in the circulation, and was associated 
with a higher mortality rate [18]. The higher mortality rate was 
attributed to death by cardiovascular disease and cancer [18]. 
It is notable that IL-6 is one of the important cytokines causing 
the liver to synthesize CRP [8]. CAP substantially increases 
the risk of heart disease across all age groups [23], so the 
mechanism behind this is likely multi-dimensional.  Based on 
the aforementioned studies, increases in CRP levels could be 
one of the mechanisms. 
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Figure 3. Associations between serum CRP and laboratory values. Scatterplots shown compare serum CRP values and other laboratory values. 
Pearson and Spearman correlations are shown above each respective scatterplot. After adjusting for multiple comparisons, none are significant.
Table 2. Patient outcomes
Outcome Low CRP
Intermediate 
CRP High CRP
Test 
statistic p-value
Time to Clinical Stability (days) † 3 [1-4] 2 [1-3] 2[1-5] X2(2)=0.5 0.800
Length of Stay (days) † 3 [1-4] 4 [2-5] 8 [5-10] X2(2)=7.2 0.030
1 year mortality ‡ 3 (30) 3 (30) 5 (50) X2(2)=1.6 0.400
† Median [Interquartile range]
‡ Frequency (percentage)
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Figure 4. Associations between urine CRP and laboratory values. Scatterplots shown compare urine CRP values and other laboratory values. 
Pearson and Spearman correlations are shown above each respective scatterplot. After adjusting for multiple comparisons, none are significant.
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Figure 5. Kaplan-Meier curve for time to clinical stability, in days, for low, 
intermediate and high urine CRP levels.
Figure 6. Kaplan-Meier curve for hospital length of stay, in days, for 
patients with low, intermediate and high urine CRP levels.
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Figure 7. Kaplan-Meier curve for time to death, in weeks, for patients 
with low, intermediate and high urine CRP values.
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To our knowledge, there have been no studies conducted to 
date to determine urine CRP levels in hospitalized patients with 
CAP.  Since urine is a non-invasive specimen type for critically 
ill patients, this would be a novel approach for monitoring CRP 
levels.  Other researchers studied urine CRP levels in patients 
with lower urinary tract symptoms (LUTS) and children with 
urinary tract infections (UTI), but CRP was not found to be a 
specific biomarker for either condition [24, 25]. In one study, 
they detected only one patient with elevated urine CRP level 
(0.86 mg/L) out of 97 patients, whereas serum CRP was 
elevated in different patients with LUTS [26]. A highly sensitive 
human CRP ELISA assay was used in this present study because 
urine CRP levels were unknown, and no other studies used this 
particular ELISA assay on urine samples. Unfortunately, there is 
no urine CRP measurement kit available for in vitro diagnostics, 
and commercially available kits are for research use only (RUO). 
The use of the highly sensitive human CRP ELISA was both a 
strength and a limitation of this study, allowing us to detect 
low quantities of CRP but creating difficulties when comparing 
results from other urine studies.  While using archived, 
processed urines was necessary for this pilot study, the use 
of fresh urine specimens would be an improvement.  Another 
weakness of the study was the number of patients in each group, 
limiting the statistical power when comparing groups.
A future prospective study with increased number of patients is 
needed for a variety of reasons.  These reasons, along with goals 
for future studies, include the following:
1) to increase the number of enrolled patients to reach 
statistical significance in some of the outcomes measured. 
For example, in patients with increased CRP levels, we 
would most likely observe more cardiovascular events and 
mortality in the long term follow up. 
2) to definitively validate the use of urine CRP level as a 
biomarker for poor outcomes in CAP patients, lending the 
test to development of point of care or at-home test for 
urine CRP. 
3) to plan interventional studies using urine CRP levels to 
monitor the effect of anti-flammatory (steroids and/or 
cytokine-specific biologics) agents with standard antibiotic 
therapy in the treatment of hospitalized patients with CAP. 
4) to define if certain antibiotics with anti-inflammatory 
properties (such as macrolides or teracycline) may add 
some benefit in terms of clinical outcomes, particularly 
with regard to cardiovascular morbitidy and mortality.
In these aforementioned future studies, we can determine if 
less inflammation ultimately increases the survival rate. If the 
data trends from the pilot study hold true in larger prospective 
studies, then there will be many useful applications for detecting 
urine CRP levels in patients with CAP.  From the laboratory 
perspective, the possibility of developing a point of care test 
for using urine to monitor CAP patients’ CRP levels is exciting. 
For example, using a simplified, rapid urine CRP test at home 
for patients with respiratory symptoms could guide whether 
they choose to stay home or seek health care.  With a point of 
care test in a hospital setting, a urine sample with a moderate 
or high CRP value would help nurses better triage patients with 
respiratory symptoms.  In conclusion, this pilot study suggests 
that measuring urine CRP levels from patients with CAP could 
be used successfully as a biomarker for starting interventions 
and improving health outcomes, ultimately leading to cost 
savings in the health care system.  
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